China Biologic Products Holding (NASDAQ:CBPO)

Thursday, March 1, 2018 | Web News
Fourth Quarter 2017 Financial Results Total sales in the fourth quarter of 2017 increased by 12.2% in RMB terms and 16.1% in USD...
Monday, January 8, 2018 | Web News
BEIJING, Jan. 8, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or...
Wednesday, January 3, 2018 | Web News
BEIJING, Jan. 3, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ( "CBPO" or the...
See All Research...

At least one FIE exists in the corporate structure

China Biologic Products, Inc., through its indirect majority-owned subsidiary, Shandong Taibang, is currently the only plasma-based biopharmaceutical company approved by the government of Shandong Province, the second largest province with a population of 93 million. The company is engaged primarily in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China.

Web site: http://www.ctbb.com.cn/

Last updated March 17, 2008